VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

rDNA-expressed S protein + alum vaccine
Vaccine Information
  • Vaccine Name: rDNA-expressed S protein + alum vaccine
  • Target Pathogen: SARS-CoV
  • Target Disease: Severe Acute Respiratory Syndrome (SARS)
  • Type: DNA vaccine
  • Status: Research
  • Host Species for Licensed Use: None
  • Host Species as Laboratory Animal Model: mouse
  • Antigen: ectodomain of the S protein(Tseng et al., 2012)
  • Immunization Route: intranasal immunization
  • Description: rDNA-expressed ectodomain of the S protein + alum vaccine (Tseng et al., 2012)
Host Response

Mouse Response

  • Host Strain: BALB/c
  • Vaccination Protocol: Each mouse received 100 µl injection of the vaccine intramuscularly on days 0 and 28. This was done at 2 µg, 1 µg, 0.5 µg, 0.5 µg of the vaccine per injection (Tseng et al., 2012)
  • Immune Response: Increased titer of neutralizing antibodies and reduced viral titer, higher titer of neutralizing antibodies without adjuvant (Tseng et al., 2012)
  • Side Effects: eosinophil infiltration in the lung lesions after challenge, lessened compared to without adjuvant (Tseng et al., 2012)
  • Challenge Protocol: On day 56 after first vaccination, each mice was challenged challenged with 10^6TCID50/60 µl of SARS-CoV intranasally (IN) and euthanized on day 58 (Tseng et al., 2012)
  • Efficacy: protected(Tseng et al., 2012)
References
Tseng et al., 2012: Tseng CT, Sbrana E, Iwata-Yoshikawa N, Newman PC, Garron T, Atmar RL, Peters CJ, Couch RB. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PloS one. 2012; 7(4); e35421. [PubMed: 22536382].